News

Roche's phase III IMmotion151 study of Tecentriq & Avastin to treat advanced/metastatic RCC meets co-primary endpoint

UK MHRA grants marketing approval to Boehringer Ingelheim’s nerandomilast to treat idiopathic pulmonary fibrosis & progressive pulmonary fibrosis

United Kingdom

Thursday, July 9, 2026, 10:00 Hrs [IST]

The Medicines and Healthcare products Regulatory Agency (MHRA) has on 8th July, 2026 approved the medicine nerandomilast (Jascayd) to treat adults with a lung disease called idiopathic pulmonary fibrosis (IPF) and

To access the full article, please log in or subscribe.

Pharma Services

Tenders & Projects

Tenders & Enquires Pharma Projects

Corporate

Company Profile Corporate Results Corporate X-ray Pharmabiz Studies of Top Companies

US FDA Update

US FDA: ANDA US FDA: Warnings US FDA: Approved NMEs US FDA: Approved NMEs US FDA: REFUSAL

Export & Import

Drug Export Procedures Drug Units With WHO GMP Certification Pharma Export Data Import Reg. Update

Pharma Laws & Documents

Notifications Pharma Regulations Patent Laws and Amendments Patent Scan Documents New Drug Approvals Notified Prices

Labs & Govt Bodies

Govt Recognised In-House R&D Units AICTE Boards & Committees List of Indian CROs List of CROs (International) Govt & approved labs of India List of State Drugs Controllers